FDA’s First “Program” Reviews: Fast Approvals, But Still Some Surprises
This article was originally published in RPM Report
The Food & Drug Administration is approving the first products under the new PDUVA V review process. The Program, as it is known, gives FDA an extra two months with an application in exchange for additional meetings for sponsors. It’s designed to help reduce the number of late-cycle “surprises.” There have been a few hiccups, but so far, it appears to be doing just that.
You may also be interested in...
Early feedback on FDA’s review “Program” for new drugs and biologics is cautiously optimistic. FDA is meeting user fee goals. Communication between reviewers and drug sponsors has dramatically improved. And even trickier applications have done unusually well at advisory committee meetings. But FDA’s John Jenkins acknowledges that a lack of resources is straining the system – and forcing the agency to adapt.
New drug approvals continued during the partial government shutdown, as user fees helped keep most of the FDA review functions running smoothly. The drug center did face some unusual challenges, including responding to a major manufacturing shutdown (by Ben Venue) – and to speculation about a leadership change at the drug center.
Genentech’s oncologic obinutuzumab is expected to be one of the first Breakthrough therapies approvals under PDUFA V. The data look game-changing for chronic lymphocytic leukemia patients. But will it result in a faster FDA review? Under the agency’s new review Program, probably not.